Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease.

Karrar A, Hariharan S, Fazel Y, Moosvi A, Houry M, Younoszai Z, Jeffers T, Zheng L, Munkhzul O, Hunt S, Monge F, Goodman Z, Younossi ZM.

Medicine (Baltimore). 2019 Aug;98(32):e16704. doi: 10.1097/MD.0000000000016704.

2.

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM.

Hepatology. 2019 Jul 4. doi: 10.1002/hep.30842. [Epub ahead of print]

PMID:
31271665
3.

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.

Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.

4.

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.

Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z.

Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664. [Epub ahead of print]

PMID:
30993748
5.

Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis.

Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA.

Clin Gastroenterol Hepatol. 2019 Feb 16. pii: S1542-3565(19)30187-9. doi: 10.1016/j.cgh.2019.02.024. [Epub ahead of print]

PMID:
30779990
6.

Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.

Karsdal MA, Hjuler ST, Luo Y, Rasmussen DGK, Nielsen MJ, Holm Nielsen S, Leeming DJ, Goodman Z, Arch RH, Patel K, Schuppan D.

Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G25-G31. doi: 10.1152/ajpgi.00158.2018. Epub 2018 Aug 30.

PMID:
30160980
7.

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.

Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL; GS-US-321-0102 Investigators.

Hepatology. 2019 Feb;69(2):684-698. doi: 10.1002/hep.30237. Epub 2019 Jan 11.

PMID:
30153359
8.

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z.

J Hepatol. 2018 Dec;69(6):1365-1370. doi: 10.1016/j.jhep.2018.08.013. Epub 2018 Aug 23.

PMID:
30144554
9.

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016.

Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM.

Medicine (Baltimore). 2018 Aug;97(31):e11518. doi: 10.1097/MD.0000000000011518.

10.

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ; GS-US-321-0105 and GS-US-321-0106 Investigators.

Gastroenterology. 2018 Oct;155(4):1140-1153. doi: 10.1053/j.gastro.2018.07.006. Epub 2018 Jul 7.

PMID:
29990488
11.

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH).

Mehta R, Shaw G, Masschelin P, Felix S, Otgonsuren M, Baranova A, Goodman Z, Younossi Z.

PLoS One. 2018 Jun 21;13(6):e0199294. doi: 10.1371/journal.pone.0199294. eCollection 2018.

12.

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.

Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z.

Hepatol Commun. 2017 Jun 6;1(5):421-428. doi: 10.1002/hep4.1054. eCollection 2017 Jul.

13.

Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.

Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, Subramanian M, McHutchison JG, Goodman Z.

Liver Int. 2018 Oct;38(10):1849-1859. doi: 10.1111/liv.13706. Epub 2018 Feb 22.

PMID:
29377462
14.

DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.

Loomba R, Gindin Y, Jiang Z, Lawitz E, Caldwell S, Djedjos CS, Xu R, Chung C, Myers RP, Subramanian GM, Goodman Z, Charlton M, Afdhal NH, Diehl AM.

JCI Insight. 2018 Jan 25;3(2). pii: 96685. doi: 10.1172/jci.insight.96685. eCollection 2018 Jan 25.

15.

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N.

Hepatology. 2018 Jul;68(1):113-126. doi: 10.1002/hep.29789. Epub 2018 May 9.

16.

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E.

Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.

17.

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.

Karsdal MA, Henriksen K, Nielsen MJ, Byrjalsen I, Leeming DJ, Gardner S, Goodman Z, Patel K, Krag A, Christiansen C, Schuppan D.

Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1009-G1017. doi: 10.1152/ajpgi.00283.2016. Epub 2016 Oct 20.

18.

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH).

Mehta R, Jeiran K, Koenig AB, Otgonsuren M, Goodman Z, Baranova A, Younossi Z.

BMC Med Genet. 2016 Sep 5;17(1):63. doi: 10.1186/s12881-016-0324-0.

19.

Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.

Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, Gonzalez T, Goodman Z, Yang Z, Jackson B, Noviello S, Albrecht JK.

J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):89-94. doi: 10.1097/MPG.0000000000001239.

PMID:
27111344
20.

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.

Friedman S, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L, Ratziu V.

Contemp Clin Trials. 2016 Mar;47:356-65. doi: 10.1016/j.cct.2016.02.012. Epub 2016 Mar 2.

Supplemental Content

Loading ...
Support Center